Fintel reports that on May 19, 2025, RBC Capital downgraded their outlook for Biohaven (NYSE:BHVN) from Outperform to Sector ...

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biohaven Ltd (Symbol: BHVN), where a total volume of 12,755 contracts has been ...

BHVN’s lead asset is Troriluzole, which is nearing a pivotal FDA decision by August 2025. The company also recently secured an additional $600 million financing through secured notes with ...

Morgan Stanley analyst Terence Flynn reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $63.00. The company’s shares closed yest ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $54.00. The company’s shares closed y ...

Biohaven Ltd. (NYSE:BHVN) shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the ...

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors ...

Nuveen Asset Management LLC raised its position in Biohaven Ltd. (NYSE:BHVN – Free Report) by 55.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange ...